Hide metadata

dc.date.accessioned2019-06-21T05:47:33Z
dc.date.available2019-06-21T05:47:33Z
dc.date.created2018-12-12T22:43:48Z
dc.date.issued2018
dc.identifier.citationKirsebom, Bjørn-Eivind Nordengen, Kaja Selnes, Per Waterloo, Knut Torsetnes, Silje Bøen Gisladottir, Berglind Brix, Britta Eugeen, Vanmechelen Bråthen, Geir Hessen, Erik Aarsland, Dag Fladby, Tormod . Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2018, 4, 617-627
dc.identifier.urihttp://hdl.handle.net/10852/68465
dc.description.abstractIntroduction The cerebrospinal fluid neurogranin (Ng)/β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) ratio may reflect synaptic affection resulting from reduced beta-amyloid (Aβ) clearance. We hypothesize that increased Ng/BACE1 ratio predicts the earliest cognitive decline in Alzheimer's disease. Methods We compared Ng/BACE1 levels between cases with subjective cognitive decline (n = 18) and mild cognitive impairment (n = 20) both with amyloid plaques and healthy controls (APOE-ε4+, n = 16; APOE-ε4-, n = 20). We performed regression analyses between cerebrospinal fluid levels, baseline hippocampal and amygdala volumes, and pertinent cognitive measures (memory, attention, Mini Mental State Examination [MMSE]) at baseline and after 2 years. Results Ng/BACE1 levels were elevated in both subjective cognitive decline and mild cognitive impairment compared to healthy controls. Higher Ng/BACE1 ratio was associated with lower hippocampal and amygdala volumes; lower baseline memory functions, attention, and MMSE; and significant decline in MMSE and memory function at 2-year follow-up. Discussion High Ng/BACE1 ratio predicts cognitive decline also in preclinical cases with amyloid plaques.
dc.languageEN
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleCerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
dc.typeJournal article
dc.creator.authorKirsebom, Bjørn-Eivind
dc.creator.authorNordengen, Kaja
dc.creator.authorSelnes, Per
dc.creator.authorWaterloo, Knut
dc.creator.authorTorsetnes, Silje Bøen
dc.creator.authorGisladottir, Berglind
dc.creator.authorBrix, Britta
dc.creator.authorEugeen, Vanmechelen
dc.creator.authorBråthen, Geir
dc.creator.authorHessen, Erik
dc.creator.authorAarsland, Dag
dc.creator.authorFladby, Tormod
cristin.unitcode185,53,82,0
cristin.unitnameKlinikk for indremedisin og laboratoriefag
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1642467
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Alzheimer's and Dementia: Translational Research and Clinical Interventions&rft.volume=4&rft.spage=617&rft.date=2018
dc.identifier.jtitleAlzheimer's and Dementia: Translational Research and Clinical Interventions
dc.identifier.volume4
dc.identifier.startpage617
dc.identifier.endpage627
dc.identifier.doihttp://dx.doi.org/10.1016/j.trci.2018.10.003
dc.identifier.urnURN:NBN:no-71619
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2352-8737
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/68465/2/article12573.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International